NCT06031610 Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
| NCT ID | NCT06031610 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | Carotid Artery Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-06-10 |
| Primary Completion | 2033-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-06-10 with a primary completion date of 2033-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RECAS is a prospective cohort of 1,000 patients with carotid artery stenosis (CAS) and undergoing revascularization therapy or standard medication treatment alone. The goal of this study is to validate whether CAS revascularization when compared to standard medication treatment alone, can effectively reduce the progression of Cerebral small vessel disease (CSVD) burden, as well as improve the severity of retinal pathologies and cognitive impairment. Therefore, Patients aged ≥ 40 years have more than 50% stenosis in unilateral carotid artery and sign informed consent will be recruited. In this study, patients will be asked to undergo Computed Tomography Angiography (CTA)/ Digital Subtraction Angiography (DSA), Computed Tomography Perfusion (CTP),multimodal Magnetic Resonance Imaging (MRI), Optical Coherence Tomography Angiography (OCTA) and neuropsychological testing. Estimated follow-up can be up to 10 years.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged ≥ 40 years. 2. ≥ 50% stenosis in unilateral carotid artery. 3. Sign informed consent. Exclusion Criteria: 1. Previous history of major head trauma and any intracranial surgery 2. Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage, and other space occupying lesions 3. Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement. 4. Severe loss of vision, hearing, or communicative ability.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06031610 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Carotid Artery Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06031610 currently recruiting?
Yes, NCT06031610 is actively recruiting participants. Contact the research team at zhangsheng@hmc.edu.cn for enrollment information.
Where is the NCT06031610 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06031610 clinical trial?
NCT06031610 is sponsored by Zhejiang Provincial People's Hospital. The trial plans to enroll 1,000 participants.